List view / Grid view
In this supplement, we've brought together a collection of interesting posters from leading companies in order to celebrate cutting-edge research in the pharmaceutical industry and to share with our readers some of the varied work being carried out by their colleagues...
In Issue #3 2017: In-Depth Focuses covering Raman Spectroscopy, Separations & Purifications, Formulation Development & Delivery; Guide To Testing Services; GMP and mutual recognition; Regulatory Insight; RMMs; Microbiology Series; and much more...
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
Dolomite Microfluidics is making microencapsulation technology more widely accessible with the Telos® droplet system, designed for high throughput and easy scale up...
Aptar Pharma has announced the installation of manufacturing capacity for its child-resistant and Senior-Friendly Classic Nasal Pump in their Congers, NY site.
The challenge of efficiently delivering a drug to its site of action, while maintaining its efficacy and minimising its potential toxicity, has received much attention in recent years, with the growing use of complex and often delicate biological molecules as therapeutic agents...
EPR Editor Steve Bremer discusses drug delivery through the skin with Shashank Jain, Formulation Research Scientist at G&W Laboratories.
24 May 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker)...
22 May 2017 | By Niamh Marriott, Junior Editor
Approximately one in four adults prescribed an antibiotic in an outpatient setting for community-acquired pneumonia does not respond to treatment...
ResistancePlus™ MG Test would bring disease and antibiotic resistance testing for potential “superbug”...
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...
4 May 2017 | By Niamh Marriott, Junior Editor
The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML...
28 April 2017 | By Niamh Marriott, Junior Editor
Novartis announced data from the MS-MRIUS study, which confirmed the effectiveness of Gilenya (fingolimod) in the real-world setting...
27 April 2017 | By Niamh Marriott, Junior Editor
Polyphor presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA)...
24 April 2017 | By Niamh Marriott, Junior Editor
BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.
